Shares of Ascendis Pharma (ASND, Financial) experienced a notable drop of 4% during morning trading, reducing the stock's value by $5.82 to $155.33. This downturn initiated shortly after the market opened.
The decline coincides with the beginning of the Committee for Medicinal Products for Human Use meeting, conducted by the European Medicines Agency. This meeting commenced at 10 AM New York time and might be influencing the current market sentiment around Ascendis Pharma.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 16 analysts, the average target price for Ascendis Pharma AS (ASND, Financial) is $210.64 with a high estimate of $293.37 and a low estimate of $164.45. The average target implies an upside of 35.62% from the current price of $155.32. More detailed estimate data can be found on the Ascendis Pharma AS (ASND) Forecast page.
Based on the consensus recommendation from 17 brokerage firms, Ascendis Pharma AS's (ASND, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Ascendis Pharma AS (ASND, Financial) in one year is $676.32, suggesting a upside of 335.44% from the current price of $155.32. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Ascendis Pharma AS (ASND) Summary page.
